|
WO2020092850A1
|
|
Materials and methods for treating cancer
|
|
CA3111804A1
|
|
Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
|
|
US2019322735A1
|
|
Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
|
|
US2019338023A1
|
|
Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
|
|
US2019284271A1
|
|
Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
|
|
US2020354443A1
|
|
Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
|
|
EP3512883A1
|
|
Epha3 antibodies for the treatment of pulmonary fibrosis
|
|
AU2009243184A1
|
|
Antibodies to granulocyte-macrophage colony-stimulating factor
|
|
AU2008226905A1
|
|
EphA3 antibodies for the treatment of solid tumors
|
|
EP3540062A1
|
|
Immunoglobulin variable region cassette exchange
|
